Dr. Li Xiaoyi

Chairman of the Board
Executive Director and CEO

Dr. Li was appointed as the chairman of the Board, an executive Director and the CEO on January 20, 2017. He is mainly responsible for the formulation of the corporate development strategies and direction for our Group as well as overall day-to-day management of our business and operations. Dr. Li Xiaoyi also holds directorship at each subsidiary of our Group since its establishment.

Dr. Li has over 25 years of experience in pharmaceutical research and development as well as management and strategic planning for pharmaceutical companies. Dr. Li founded Lee’s Pharm in 1994 and has been the chief technical officer since then. Dr. Li was appointed as an executive director and the chief executive officer of Lee’s Pharm in September 2003, where he is responsible for the overall operations and management and research and development of Lee’s Pharm. Dr. Li will resign as the chief technical officer, the chief executive officer and executive director of Lee’s Pharm before the Listing.

In addition to his roles in Lee’s Pharm, Dr. Li also has multiple experience in the management and strategic planning for many other pharmaceutical institutions. Since 2014, he has been serving as the vice president of Hong Kong Biotechnology Organization, mainly responsible for developing the biotech industry in Hong Kong. Since March 2016, he has been serving as the president of Guangzhou Pharmaceutical Association (广州药学会), an academic and non-profit social organization formed by pharmaceutical researchers in Guangzhou, where he is mainly responsible for providing industrial insights for developing the pharmaceutical industry in Guangzhou. Dr. Li is also a member of the review committee of Innovation and Technology Fund of Hong Kong Government, a fund supported by the government of Hong Kong to promote and facilitate technology companies.

Dr. Li obtained his Ph.D. in pharmacology from the medicine college of the University of Illinois in the United States in May 1992.

Dr. Li has earned multiple awards and esteemed recognitions. He has been an adjunct professor at the Hong Kong University of Science and Technology since November 2013 and an honorary fellow since June 2016. In August 2018, he was awarded the leading innovation talent (广州创新领军人才) by the Guangzhou government. In January 2018, Dr. Li was appointed as a member of the People’s Political Consultative Conference of Anhui Province in the PRC, and was honored with the 16th World Outstanding Chinese Award (世界杰出华人奖) by the World Chinese Business Investment Foundation (世界华商投资基金会) in August 2018.

Dr. Lau Lit Fui

President and Chief
Operating Officer

Dr. Lau joined our Group in June 2016 and was appointed as president and chief operating officer of our Group on April 1, 2019. He is primarily responsible for overseeing the overall operation of our Group.

Dr. Lau has 23 years of extensive experience in operation management and research and development of new drugs. From August 1998 to January 2008, he worked in the global research and development department of Pfizer Inc., a worldwide leading pharmaceutical company, where his last position was senior principal scientist heading a biology laboratory and supervising technicians in testing drug candidates. From January 2008 to August 2012, Dr. Lau worked as the associate director of the new product and alliance development department of GlaxoSmithKline (China) R&D Co., Ltd., a science-led global healthcare company, where he was responsible for department management and research and development of new drugs treating neurodegenerative diseases. Dr. Lau joined Lee’s Pharm in October 2012 and had been managing the operation and research and development of Lee’s Pharm until April 2016.

Dr. Lau obtained both his bachelor’s degree in science and master degree of philosophy from The Chinese University of Hong Kong in December 1985 and December 1987, respectively, where he was awarded the Wong Siew Chan Scholarship. In December 1993, he obtained his Ph.D. in biochemical science from the University of Connecticut in the United States. He completed his research fellowship in neuroscience at the School of Medicine of John Hopkins University in the United States in August 1998.

Dr. Lau’s outstanding performances have been recognized by several leading corporations. In February 1991, he was granted SmithKline Beecham Student Pharmacology Award by SmithKline Beecham Pharmaceuticals, a company focused on pharmaceuticals, biologics, vaccines, and consumer healthcare. During his employment with Pfizer, Inc., he was granted several awards by the global research & development department of the company, for his leadership, team work spirit and contribution in research and development. In 2014, he was awarded the Medicines for Life Award by UTASIA Inc., a subsidiary of United Therapeutics Corporation, a company mainly focusing on pharmaceutical preparations business. In 2018, Dr. Lau received an award from CVie Therapeutics Co. Ltd., a subsidiary of Lee’s Pharm, for his sustained contribution and commitment.

Dr. Albert Tsai Jr.

Chief Medical Officer

Dr. Albert Tsai Jr. joined the Company as the Chief Medical Officer in June 2021 and is primarily responsible for leading the Group to advance its assets through the clinical development process as well as supporting the post approval medical affairs for the Group’s commercial products (e.g. safety, risk management, thought leader relationships). In addition, Dr. Tsai will provide strategic direction for therapeutic indication development, and contribute to the overall corporate strategy and a culture of innovation and excellence to position the Group as a leader in ophthalmology in Asia-Pacific region.

Dr. Tsai has 20 years of healthcare experience across the spectrum of pharmaceuticals, biotech, medical devices and healthcare consulting, as well as in various country markets including China, US, Japan and Southeast Asia. From 2019 to 2021, he served as the Vice President, Regional Medical Officer of the Asia-Pacific region at PPD Inc., a leading global Contract Research Organization (CRO), responsible for business development and providing medical/scientific product development advisory to biotech companies in Asia. Prior to that, he served as Vice President, Asia Pacific at The Medicines Company Hong Kong (NASDAQ: MDCO) from 2014–2019, where he developed and implemented the Asia expansion strategy for The Medicines Company Hong Kong with a primary focus on establishing their presence in China and Japan. From 1997–2014, he worked in various leading global pharmaceutical companies including Bayer Schering Pharma AG, Merck Sharp & Dohme (Asia) Ltd., Amgen Inc. and GE Healthcare Inc. in senior medical positions.

r. Tsai’s healthcare experience varies not only in sub-sectors, but also in function and therapeutic area. He has held commercial roles as well as research and development/medical affairs roles and a demonstrable track-record in handling in-licensing products for commercial partners, therefore he has a broad understanding of various aspects of the industry.

Dr. Tsai obtained his Doctor of Medicine (MD) from Northwestern University and Master of Business Administration: Strategy and Finance (MBA) from University of Southern California.

Dr. Li Lok Yee Mandy

Senior Vice President, R&D

Dr. Li joined Lee' s Pharm February 2014, and further promoted to a senior vice president of Lee’s Pharm, leading and managing Lee's Pharm's research and development center. Dr. Li was appointed as the senior vice president, R&D of our Group on September 1 2020.She is mainly responsible for facilitating the business development and execution of scientific strategies of research and project management (including both in-licensed and in-house developed pipeline products) of our Group.

Dr. Li obtained her bachelor of science degree in biochemistry and her Ph.D. in biochemistry from The Chinese University of Hong Kong, in December 2000 and December 2004, respectively. From 2004 to 2006, Dr. Li worked as a research associate at the department of chemical pathology of The Chinese University of Hong Kong. From 2006 to 2007, she worked as a post-doctoral fellow at the department of surgery of The University of Hong Kong. From October 2007 to April 2010, Dr. Li served as a research scientist of Bio-Cancer Treatment International Limited, a Hong Kong company focused on the research and development of innovative anticancer drugs, where she led a research team to conduct research on innovative anti-cancer, playing an active role in responding to FDA queries.

Mr. Zhang Guohui

Deputy General Manager

Mr. Zhang joined our Group in June 2016 and was appointed as deputy general manager of our Group on July 1, 2016. He is mainly responsible for overseeing production and quality control of our Group.

Mr. Zhang has over 23 years of experience in pharmaceutical industry. Since his graduation in July 1997 and until June 2016, Mr. Zhang had been working in Lee’s Pharm for more than 18 years. He was first responsible for the research and development of new drugs, quality control and good manufacturing practice management and further promoted as the head of research and development of the company, where he accumulated extensive experience in the research and development and registration of new drugs, as well as project management.

Mr. Zhang obtained his bachelor’s degree in biochemical engineering from the Beijing Institute of Light Industry (北京轻工业学院), currently known as Beijing Technology and Business University (北京工商大学) in Beijing, China in July 1997. He obtained his master’s degree in business administration from Asia International Open University (Macau) in January 2009.

Mr. Jiang Su

CLINICAL OPERATIONS DIRECTOR

Mr. Jiang joined our Group in January 2018 and was appointed as the clinical operations director of our Group on June 1, 2019. He is mainly responsible for conducting and organizing clinical trials.

Mr. Jiang has over 17 years of experience in pharmaceutical industry. Since his graduation in July 2003 and until January 2018, Mr. Jiang had been working in Lee’s Pharm for almost 15 years. He was first responsible for carrying out clinical trials and further promoted to the head of clinical quality in charge of quality control of clinical trials.

Mr. Jiang obtained his bachelor’s degree in maternal and child health from the Anhui Medical University (安徽医科大学) in Anhui Province, China in June 2003.

Ms. Feng Xinyan

CHIEF FINANCIAL OFFICER

Ms. Feng was appointed as the chief financial officer of our Group on December 7, 2020. She is primarily responsible for financial planning and initiatives and investor relations management of our Group.

From 2000 to 2002, she worked as an analyst at McKinsey & Company. From August 2004 to July 2012, she worked at Goldman Sachs (Asia) L.L.C., and successively held various positions. including the executive director. From July 2012 to September 2014, she served as managing director and head of China equity capital markets at Standard Chartered Bank. From September 2014 to August 2018, she served as executive director of strategic business development and investor relations at Global Brands Group Holding Limited, a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 0787). She served as chief financial officer at ACEA Therapeutics, Inc, a company engaged in developing and delivering innovative treatments to life-threatening diseases from April 2019 to November 2019.

Ms. Feng obtained her bachelor’s degree in computer appliance from Fudan University (复旦大学) in Shanghai, China in July 1998. She obtained a master’s degree in computer science from University of Virginia in the United States in August 2000, and a master of business administration degree from the University of Chicago Booth School of Business in the United States in March 2004.

Mr.Mauro Bove

Business Development Director

Mr. Bove was appointed as the business development director of our Group on January 1, 2019. He is mainly responsible for overseeing business development activities and identifying new business opportunities and finalizing the relevant negotiations on a global basis.

Mr. Bove has almost 40 years of business and management experience within the pharmaceutical industry working in Europe, North America and Asia. Mr. Bove led for many years until March 2014 the corporate and business development of Sigma-Tau Finanziaria S.p.A.

From May 2005 to December 2014, he served as a non-executive director of Lee’s Pharm. From December 2014 to December 2018, he served as the senior vice president of corporate and business development department of Lee’s Pharm, overseeing the business development activities and identifying new business opportunities for the group.

Mr. Bove obtained his law degree from the University of Parma in Italy in July 1980. In 1985, he attended the Academy of American and International Law at International and Comparative Law Center in Texas, the United States.

Mr. Feng Jiang

Sales and Marketing Director

Mr. Feng was appointed as sales and marketing director of our Group on October 1, 2020. He is primarily responsible for overseeing the branding, sales and marketing activities of our Group.

From 2000 to 2006, Mr. Feng served at various China offices of multinational pharmaceutical companies as sales or medical representative. From January 2007 to April 2010, he worked for Eli Lilly Asia, Inc., where he was responsible for the promotion and sales of products in Guangdong Province and his last position was regional manager. From April 2010 to September 2020, he served successively as the regional manager and deputy director of the ophthalmic business department of Allergan Information Consulting (Shanghai) Co., Ltd, where he was responsible for the sales and marketing of the company’s ophthalmic pharmaceutical products and was granted several awards by the company in recognition of his great performance.

Mr. Feng obtained his bachelor’s degree in biotechnology from South China Agricultural University (华南农业大学) in Guangdong Province, China in July 1999.

Ms. Yau Suk Yan

Financial Controller
and Company Secretary

Ms. Yau was appointed as the financial controller and the company secretary of our Company on September 9, 2019. She is responsible for management and supervision of auditing, report analysis and budget control of our Group.

From September 2004 to January 2010, Ms. Yau served as a manager at KPMG. From February 2010 to July 2015, she was the financial controller and company secretary of Active Group Holdings Limited, currently known as Sino Energy International Limited (中能国际控股集团有限公司), a company whose shares are listed on the Main Board of the Stock Exchange (stock code: 1096), where she was in charge of finance management and audit of the group. From July 2015 to September 2019, Ms. Yau served as the financial controller and company secretary of Uni-Bio Science Group Limited (联康生物科技集团), a company whose shares are listed on the Main Board of Stock Exchange (stock code: 690), where she was responsible for finance management and audit of the group.

Ms. Yau obtained her bachelor’s degree of arts (with honors) in accountancy from the Hong Kong Polytechnic University in November 2004 and completed the CPA qualification programme and passed the professional examination for membership admission and was issued with a practicing certificate by Hong Kong Institute of Certified Public Accountants in August 2006. She has been a certified public accountant of the Hong Kong Institute of Certified Public Accountants since January 2008 and a fellow member of the Hong Kong Institute of Certified Public Accountants since March 2016.

Dr. Jin Yixuan

Associate Medical Director

Dr. Jin joined our Group as the associate medical director on October 8, 2019, mainly responsible for overseeing clinical trial development in terms of protocol development and providing medical insight for clinical trial strategy and model design.

Dr. Jin started her career as an attending physician of ophthalmology in Nanhai People’s Hospital of Foshan City (佛山市南海区人民医院) from 2011 to 2014. She worked at Beijing Novartis Pharma Co., Ltd. (北京诺华制药有限公司), a global healthcare company from June 2018 to September 2019, where her last position was medical science liaison manager.

Dr. Jin obtained her master’s degree in clinical medicine from Harbin Medical University (哈尔滨医科大学) in Heilongjiang Province, China, in July 2008. She then obtained her doctor’s degree in ophthalmology from Sun Yat-sen University (中山大学) in Guangdong Province, China in June 2011.

Mr. Ma Jian

Senior Manager of Quality Control

Mr. Ma joined our Group in January 2017. He was appointed as assistant manager of quality assurance and quality control on September 1, 2018, and was further promoted as the senior manager of quality control of our Group in August 2020. He is mainly responsible for devising procedures to inspect and report quality assurance issues, identifying critical control points and preventive measures.

From 2007 to 2012, Mr. Ma had been working in the R&D department of various pharmaceutical companies. From March 2012 to January 2017, Mr. Ma had been working at Lee’s Pharm where he was first the leader of document quality assurance group and further promoted as the leader of onsite quality assurance.

Mr. Ma obtained his bachelor’s degree in medicine from Anhui Medical University (安徽医科大学) in Anhui Province, China in June 2007.

Mr. Zhang Xingshuan

Deputy Manager
of Production

Mr. Zhang joined our Group in January 2017 and was appointed as the deputy manager of production on November 1, 2017. He is mainly responsible for overseeing production process for clinical sample, monitoring productivity rates and product standards and implementing quality control programs.

From February 2012 to December 2016, Mr. Zhang worked at Lee’s Pharm Hefei where he was responsible for production and system management.

Mr. Zhang obtained his college degree in traditional Chinese medicine pharmaceutical technology from Bozhou Vocational and Technical College (亳州职业技术学院) in Anhui Province, China in July 2008 and his bachelor’s degree in traditional Chinese medicine (online course) from Anhui University of Chinese Medicine (安徽中医药大学) in Anhui Province, China in January 2015.

Dr. Samir
Chandrakant Patel

Strategy Consultant

Dr. Patel was engaged by our Company as strategy consultant of our Group on April 9, 2020, to provide our Group with consulting services in relation to, among others, planning business strategies, sourcing business development opportunities, and providing protocol inputs and clinical development integration inputs.

Dr. Patel has over thirty years of extensive experience in ophthalmology, including 10 years in academic medicine and 20 years in the ophthalmic pharmaceutical industry. He obtained his degree of doctor of medicine from the medical school of University of Massachusetts in the United States in 1985 and completed his residency in ophthalmology at the University of Chicago in 1990. Further, Dr. Patel completed his clinical retinal fellowship at the Massachusetts Eye and Ear Infirmary at the Harvard Medical School, being the primary teaching hospital of Harvard Ophthalmology. Dr. Patel was duly elected as a fellow by the American Academy of Ophthalmology in 1992. Dr. Patel commenced his practice in academic ophthalmology at the University of Chicago in 1992 where he eventually served as an associate professor of ophthalmology and the director of retina service, until July 2000.

Dr. Patel further gained valuable insights and experience in the management and operation of pharmaceutical companies since 2000 when he first started his own business by co-founding Eyetech Pharmaceuticals, Inc., a biopharmaceutical company specializing in novel therapeutics to treat eye diseases, where he served as a director and chief of clinical and commercial strategy. In 2007, Dr. Patel co-founded Ophthotech Corporation, a biopharmaceutical company listed on the NASDAQ under the ticker symbol “OPHT” and specializing in the development of novel therapeutics to treat ophthalmic diseases (currently known as IVERIC bio, Inc. and listed on the NASDAQ Global Select Market under the ticker symbol “ISEE”), and served as the company’s founding CEO, president and vice chairman of its board of directors.